| scholarly article | Q13442814 |
| P2093 | author name string | Dave S B Hoon | |
| Makoto Nagahara | |||
| Shigeshi Ono | |||
| Stella Lam | |||
| P2860 | cites work | Detection of microRNA expression in human peripheral blood microvesicles | Q21144210 |
| The RIN: an RNA integrity number for assigning integrity values to RNA measurements | Q21263010 | ||
| Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia | Q24539231 | ||
| Circulating microRNAs are new and sensitive biomarkers of myocardial infarction | Q24606701 | ||
| Systematic comparison of microarray profiling, real-time PCR, and next-generation sequencing technologies for measuring differential microRNA expression | Q24634173 | ||
| Circulating microRNAs as stable blood-based markers for cancer detection | Q24652098 | ||
| MicroRNA profiling: approaches and considerations | Q26861675 | ||
| Direct serum assay for microRNA-21 concentrations in early and advanced breast cancer. | Q51535040 | ||
| U6 is not a suitable endogenous control for the quantification of circulating microRNAs. | Q54182683 | ||
| Circulating microRNAs as novel biomarkers for platelet activation. | Q54277423 | ||
| Analysis of circulating microRNA: preanalytical and analytical challenges. | Q54378210 | ||
| Circulating microRNAs in patients with coronary artery disease. | Q54421687 | ||
| Serum microRNA signatures identified in a genome-wide serum microRNA expression profiling predict survival of non-small-cell lung cancer. | Q54439228 | ||
| miR-Test: A Blood Test for Lung Cancer Early Detection | Q56779122 | ||
| Impact of intravenous heparin on quantification of circulating microRNAs in patients with coronary artery disease | Q61668954 | ||
| Do platform-specific factors explain microRNA profiling disparities? | Q82315386 | ||
| Short structured RNAs with low GC content are selectively lost during extraction from a small number of cells | Q84503442 | ||
| Quantification of circulating miRNAs in plasma: effect of preanalytical and analytical parameters on their isolation and stability | Q87328732 | ||
| A direct plasma assay of circulating microRNA-210 of hypoxia can identify early systemic metastasis recurrence in melanoma patients | Q35740150 | ||
| Assessment of small RNA sorting into different extracellular fractions revealed by high-throughput sequencing of breast cell lines. | Q35770652 | ||
| Plasma components affect accuracy of circulating cancer-related microRNA quantitation | Q35917691 | ||
| Association between circulating tumor cells and prognosis in patients with stage III melanoma with sentinel lymph node metastasis in a phase III international multicenter trial | Q36339707 | ||
| MicroRNA detection by microarray | Q37365284 | ||
| Changes in circulating microRNAs after radiochemotherapy in head and neck cancer patients. | Q37438786 | ||
| Digital PCR quantification of miRNAs in sputum for diagnosis of lung cancer | Q37504443 | ||
| Exploration of genome-wide circulating microRNA in hepatocellular carcinoma: MiR-483-5p as a potential biomarker. | Q37659419 | ||
| Diagnostic and prognostic value of circulating tumor-related DNA in cancer patients. | Q38152782 | ||
| Circulating microRNA biomarker studies: pitfalls and potential solutions | Q38267750 | ||
| Exosomes from bone marrow mesenchymal stem cells contain a microRNA that promotes dormancy in metastatic breast cancer cells. | Q38978972 | ||
| Robust microRNA stability in degraded RNA preparations from human tissue and cell samples | Q39717005 | ||
| Dynamic regulation of circulating microRNA during acute exhaustive exercise and sustained aerobic exercise training. | Q39737335 | ||
| Differential profiling of human red blood cells during storage for 52 selected microRNAs | Q39900387 | ||
| Cell-free microRNAs: potential biomarkers in need of standardized reporting | Q39946127 | ||
| The digital MIQE guidelines: Minimum Information for Publication of Quantitative Digital PCR Experiments | Q40103939 | ||
| Effect of long-term storage in TRIzol on microarray-based gene expression profiling | Q41835256 | ||
| Analysis of circulating microRNA biomarkers in plasma and serum using quantitative reverse transcription-PCR (qRT-PCR). | Q41875540 | ||
| Analyzing the circulating microRNAs in exosomes/extracellular vesicles from serum or plasma by qRT-PCR. | Q41953389 | ||
| Profiles of differential expression of circulating microRNAs in hepatitis B virus-positive small hepatocellular carcinoma | Q42176710 | ||
| Anticoagulants interfere with PCR used to diagnose invasive aspergillosis. | Q42833328 | ||
| Guidelines for the use of RNA purification kits. | Q42963670 | ||
| Purification of RNA using TRIzol (TRI reagent). | Q43048322 | ||
| Direct serum assay for microRNA in cancer patients. | Q44783401 | ||
| Heparin selectively affects the quantification of microRNAs in human blood samples | Q45236324 | ||
| Plasma microRNA panel to diagnose hepatitis B virus-related hepatocellular carcinoma | Q45361542 | ||
| Evaluation of quantitative miRNA expression platforms in the microRNA quality control (miRQC) study | Q48296508 | ||
| Combinatorial microRNA target predictions | Q27860510 | ||
| Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight? | Q27860893 | ||
| MicroRNAs: genomics, biogenesis, mechanism, and function | Q27861070 | ||
| The 21-nucleotide let-7 RNA regulates developmental timing in Caenorhabditis elegans | Q27861103 | ||
| Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases | Q28131780 | ||
| microRNAs: tiny regulators with great potential | Q28214699 | ||
| The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments | Q28236560 | ||
| miR-15a and miR-16-1 in cancer: discovery, function and future perspectives | Q28247489 | ||
| Causes and consequences of microRNA dysregulation in cancer | Q28258994 | ||
| Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival | Q28264400 | ||
| A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia | Q28279141 | ||
| Serum microRNA biomarkers for detection of non-small cell lung cancer | Q28731643 | ||
| MicroRNA biogenesis: coordinated cropping and dicing | Q29547496 | ||
| Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma | Q29614238 | ||
| The microRNA spectrum in 12 body fluids | Q29618068 | ||
| Comparing the MicroRNA spectrum between serum and plasma | Q31080442 | ||
| Reproducibility of quantitative RT-PCR array in miRNA expression profiling and comparison with microarray analysis | Q33498129 | ||
| A five-microRNA panel in plasma was identified as potential biomarker for early detection of gastric cancer | Q33555195 | ||
| Profiles of extracellular miRNAs in the aqueous humor of glaucoma patients assessed with a microarray system | Q33671943 | ||
| Purification and characterization of PCR-inhibitory components in blood cells | Q33971131 | ||
| MicroRNAs in renal cell carcinoma: diagnostic implications of serum miR-1233 levels | Q34045027 | ||
| Vesicle-related microRNAs in plasma of nonsmall cell lung cancer patients and correlation with survival. | Q34123686 | ||
| Circulating miRNA markers show promise as new prognosticators for multiple myeloma | Q34135498 | ||
| Cell-free nucleic acids as biomarkers in cancer patients | Q34184393 | ||
| Association of circulating miR-223 and miR-16 with disease activity in patients with early rheumatoid arthritis. | Q34237586 | ||
| Plasma microRNA profiles: identification of miR-25 as a novel diagnostic and monitoring biomarker in oesophageal squamous cell carcinoma | Q34354560 | ||
| Liquid biopsy: monitoring cancer-genetics in the blood | Q34356149 | ||
| Standardization of sample collection, isolation and analysis methods in extracellular vesicle research | Q34369038 | ||
| Circulating miR-17, miR-20a, miR-29c, and miR-223 combined as non-invasive biomarkers in nasopharyngeal carcinoma | Q34441361 | ||
| Plasma processing conditions substantially influence circulating microRNA biomarker levels | Q34769479 | ||
| Epigenetics and genetics. MicroRNAs en route to the clinic: progress in validating and targeting microRNAs for cancer therapy | Q35039281 | ||
| Changes in circulating microRNA-126 during treatment with chemotherapy and bevacizumab predicts treatment response in patients with metastatic colorectal cancer. | Q35098328 | ||
| A critical evaluation of microRNA biomarkers in non-neoplastic disease | Q35107632 | ||
| Diagnosis of lung cancer in individuals with solitary pulmonary nodules by plasma microRNA biomarkers | Q35218751 | ||
| Circulating micro-RNA expression profiles in early stage nonsmall cell lung cancer | Q35675384 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 10 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | biopsy | Q179991 |
| microRNA | Q310899 | ||
| biomarker | Q864574 | ||
| P304 | page(s) | 1890-907 | |
| P577 | publication date | 2015-01-01 | |
| P1433 | published in | Journal of Clinical Medicine | Q27724774 |
| P1476 | title | Circulating microRNA Biomarkers as Liquid Biopsy for Cancer Patients: Pros and Cons of Current Assays | |
| P478 | volume | 4 |
| Q36091092 | A restricted signature of serum miRNAs distinguishes glioblastoma from lower grade gliomas |
| Q62132626 | CRISPR Technology for Breast Cancer: Diagnostics, Modeling, and Therapy |
| Q92734019 | Challenges in Using Circulating Micro-RNAs as Biomarkers for Cardiovascular Diseases |
| Q47151532 | Circulating MicroRNAs As Potential Biomarkers for Veterinary Infectious Diseases |
| Q92594244 | Circulating Tumour Cells, Circulating Tumour DNA and Circulating Tumour miRNA in Blood Assays in the Different Steps of Colorectal Cancer Management, a Review of the Evidence in 2019 |
| Q26748862 | Circulating long non-coding RNAs in cancer: current status and future perspectives |
| Q26767346 | Circulating microRNAs as Potential Biomarkers in Non-Alcoholic Fatty Liver Disease and Hepatocellular Carcinoma |
| Q37643903 | Circulating microRNAs as Potential Biomarkers of Infectious Disease |
| Q93109146 | Clinical Translatability of "Identified" Circulating miRNAs for Diagnosing Breast Cancer: Overview and Update |
| Q42390428 | Correction: Ono, S.; Lam, S.; Nagahara, M.; Hoon, D.S.B. Circulating microRNA Biomarkers as Liquid Biopsy for Cancer Patients: Pros and Cons of Current Assays. J. Clin. Med. 2015, 4, 1890-1907. |
| Q98386387 | Downregulation of the let-7 family of microRNAs may promote insulin receptor/insulin-like growth factor signalling pathways in pancreatic ductal adenocarcinoma |
| Q90376934 | Dysregulation of a novel miR-1825/TBCB/TUBA4A pathway in sporadic and familial ALS |
| Q89860577 | Exosomal Non Coding RNA in LIQUID Biopsies as a Promising Biomarker for Colorectal Cancer |
| Q38867417 | Extracellular miRNAs as biomarkers in cancer |
| Q92615593 | Hydrogel-Coated Microneedle Arrays for Minimally Invasive Sampling and Sensing of Specific Circulating Nucleic Acids from Skin Interstitial Fluid |
| Q64935494 | Identification of a six-miRNA panel in serum benefiting pancreatic cancer diagnosis. |
| Q52586808 | Improved Detection of Circulating MiRNAs in Serum and Plasma Following Rapid Heat/Freeze Cycling. |
| Q39157824 | Integrating liquid biopsies into the management of cancer |
| Q39142265 | Liquid Biopsy for Cancer: Circulating Tumor Cells, Circulating Free DNA or Exosomes? |
| Q52669514 | Liquid Biopsy in Head and Neck Cancer: Promises and Challenges. |
| Q42421291 | Liquid biopsies for liquid tumors: emerging potential of circulating free nucleic acid evaluation for the management of hematologic malignancies |
| Q94940502 | Liquid biopsy for breast cancer using extracellular vesicles and cell-free microRNAs as biomarkers |
| Q38700529 | Liquid biopsy utility for the surveillance of cutaneous malignant melanoma patients |
| Q91845076 | Measure Twice: Promise of Liquid Biopsy in Pediatric High-Grade Gliomas |
| Q45943889 | Measuring plasma levels of three microRNAs can improve the accuracy for identification of malignant breast lesions in women with BI-RADS 4 mammography. |
| Q35918422 | MicroRNAs as Biomarkers for Acute Atrial Remodeling in Marathon Runners (The miRathon Study--A Sub-Study of the Munich Marathon Study). |
| Q50123796 | MicroRNAs as biomarkers for human glioblastoma: progress and potential. |
| Q42317922 | MicroRNAs for the Prediction of Early Response to Sorafenib Treatment in Human Hepatocellular Carcinoma |
| Q64073804 | Orphan noncoding RNAs: novel regulators and cancer biomarkers |
| Q94572487 | Plasma or serum? A qualitative study on rodents and humans using high-throughput microRNA sequencing for circulating biomarkers |
| Q54918383 | Serum miR-22 as potential non-invasive predictor of poor clinical outcome in newly diagnosed, uniformly treated patients with diffuse large B-cell lymphoma: an explorative pilot study. |
| Q47769995 | Targeting Hypoxia to Improve Non-Small Cell Lung Cancer Outcome |
| Q92074628 | Technological Challenges and Future Issues for the Detection of Circulating MicroRNAs in Patients With Cancer |
| Q59797807 | The Influence of Pre-Analytical Factors on the Analysis of Circulating MicroRNA |
| Q30363613 | Toward reliable biomarker signatures in the age of liquid biopsies - how to standardize the small RNA-Seq workflow |
| Q41346578 | Urine miR-21-5p as a potential non-invasive biomarker for gastric cancer |
Search more.